Skip to main content

Table 2 Changes of BASDAI, pain VAS scores, and Morning stiffness-VAS scores

From: Efficacy of wIRA in the treatment of sacroiliitis in male patients with ankylosing spondylitis and its effect on serum VEGF levels

  wIRA group (n = 120) Control group (n = 120) Difference d t-statistic P value 95% CI
BASDAI
 Before T* 8.33 ± 0.71 8.36 ± 0.74 − 0.04 ± 0.35 − 0.632 0.531 − 0.15~0.08
 After T 7.65 ± 0.65 7.90 ± 0.62 − 0.26 ± 0.56 − 2.907 0.000 − 0.44~− 0.08
 Difference d 0.68 ± 0.46 0.45 ± 0.49 0.35 ± 0.50
 95% CI 0.53~0.83 0.30~0.61 0.24–0.47
P value 0.000 0.000 0.000
Pain VAS scores
 Before T 8.85 ± 0.48 8.82 ± 0.45 0.03 ± 0.34 0.605 0.549 − 0.08~0.14
 After T 7.30 ± 0.65 7.77 ± 0.46 − 0.46 ± 0.54 − 5.436 0.000 − 0.63~− 0.29
 Difference d 1.55 ± 0.49 1.05 ± 0.35 0.27 ± 0.48
 95% CI 1.39~1.70 0.94~1.16 0.16–0.37
P value 0.000 0.000 0.000
Morning stiffness VAS scores
 Before T 8.81 ± 0.46 8.75 ± 0.50 0.06 ± 0.37 1.071 0.291 − 0.06~0.18
 After T 7.26 ± 0.59 7.80 ± 0.55 − 0.54 ± 0.55 − 6.205 0.000 − 0.72~− 0.36
 Difference d 1.55 ± 0.50 0.95 ± 0.35 0.28 ± 0.50
 95% CI 1.38~1.71 0.83~1.06 0.17–0.39
P value 0.000 0.000 0.000
  1. T treatment, BASDAI bath ankylosing spondylitis disease activity index, VAS visual analogue scale, CI confidence interval
  2. *Before treatment: wIRA treatment (before the start of the first stage of treatment regimen A and before the start of the second stage of treatment regimen A); control group (before the start of the first stage of treatment regimen B and before the start of the second stage of treatment regimen A). After treatment: values before the corresponding treatment regimen and after the corresponding treatment regimen